were among the best-performing health-related stocks Monday, soaring 23% after the imaging systems company agreed to be acquired by
Caliper Life Sciences
( CALP) for roughly $80 million in stock and warrants.
"The acquisition is a defining step in Caliper's strategic transformation into a leading provider of tools and services that increase the productivity and clinical relevance of life sciences research, and is expected to accelerate Caliper's revenue growth and profitability," the companies said in a press release. The acquisition is expected to add to Caliper's earnings in 2006 and 2007, as measured by earnings before interest, taxes, depreciation, amortization and restructuring charges. The deal is expected to close during the second quarter. Shares of Xenogen were trading up 66 cents to $3.55, while shares of Caliper Life Sciences were trading up 20 cents to $5.65.
China Medical Technologies
( CMED) jumped 13% after the medical device company posted solid third-quarter earnings and sales growth. The company earned $7.1 million, or 26 cents per American Depository share, on sales of $13.7 million, for the third quarter ended Dec. 31. The earnings gain represents an increase of 42% over last year's results, while sales grew by about 62%.
Looking ahead, China Medical Technologies continues to expect fiscal 2006 earnings of $21.7 million to $23.5 million, with sales of $44.6 million to $49.6 million. Shares were up $4.20 to $37.69.
rose 1% after the company posted a higher fourth-quarter profit, even though the results missed Wall Street expectations. The medical device company earned $12 million, or 43 cents a share, up from $8.5 million, or 30 cents a share, a year earlier. Sales rose to $23.7 million from $17.5 million a year earlier. Analysts polled by Thomson First Call expected earnings of 46 cents a share on sales of $24.3 million.
For the first quarter, Syneron projects sales that will be roughly flat compared with the just-completed fourth-quarter results. For the full year, the company sees sales of $113 million to $120 million. Analysts project first-quarter sales of $27 million and full-year sales of $117.5 million. Shares were trading up 33 cents to $28.31.
( ENCY) traded actively after the biopharmaceutical company posted better-than-expected fourth-quarter results. The company reported a loss of $19.4 million, or 33 cents a share, on sales of $5.6 million. Analysts expected a bigger loss of 36 cents a share, with sales of $3.5 million. During the year-earlier period, the company recorded a loss of $14.7 million, or 26 cents a share, on sales of $4.8 million. Shares were trading down 13 cents to $8.88.
Albany Molecular Research
fell 5% after the company reported mixed fourth-quarter results. The company posted a loss of $942,000, or 3 cents a share, on total sales of $39.1 million. Excluding items, the company had a loss of $172,000, or 1 cent a share. Analysts expected a profit of 6 cents a share, before items, on sales of $37.2 million. During the year-earlier quarter, the company reported adjusted earnings of $5.4 million, or 17 cents a share, on sales of $46.1 million. Recurring royalties from the antihistamine Allegra fell to $6.2 million during the latest period, down significantly from year-earlier royalties of $12.2 million. The royalties were hurt by the launch of a generic version of Allegra's main ingredient, the company said.
Looking ahead, Albany Molecular sees first-quarter contract revenue of $29 million to $32 million, a decline of 14% to 22% from last year's first quarter. Shares were trading down 52 cents to $10.78.
Other health-care volume movers included
, down 24 cents to $25.44;
, up 26 cents to $22.66;
( GNTA), up 1 cent to $2.81;
( SGP), down 6 cents to $18.34;
Johnson & Johnson
, down 19 cents to $58.20;
, down 7 cents to $21.79;
, down 68 cents to $70.77;
Teva Pharmaceutical Industries
, up 25 cents to $40.95;
, up 12 cents to $14.20;
, down 12 cents to $34.19; and
( DNA), down $1.80 to $81.72.